Effect of α-Lipoic Acid on Oxidative Stress in End-Stage Renal Disease Patients Receiving Intravenous Iron

Table 1

Baseline values for control and intervention visits.

Variable	Control visit	Intervention visit	P value
Hemoglobin (g/dL)	12.85 (11.6, 14)	13 (11.7, 13.7)	0.675
Hematocrit (%)	38.94±3.68	39.57±3.42	0.718
Serum albumin (g/dL)	3.79±0.27	3.86±0.34	0.679
Serum iron (μg/dL)	68±12	79±23	0.170
Total iron binding capacity (μg/dL)	256±49	234±38	0.280
Transferrin saturation (%)	27 (24, 28)	31 (30, 36)	0.010
Serum ferritin (ng/mL)	570±241	617±397	0.880
Malondialdehyde (μmol/L)	9.04±5.29	9.12±5.16	0.973
Lipid hydroperoxide (pg/mL)	1.86±0.78	1.86±0.73	0.943
F2 isoprostanes (μmol/L)	37.07±13.28	30.04±6.89	0.161

Values are expressed as mean ± SD or median (interquartile range). Wilcoxon signed-rank test was used for hemoglobin and transferrin saturation; paired 𝑡-test was used for all other variables.